Novo Holdings Completes Acquisition of Catalent
Summary
Catalent plays a key role in driving product development, launch and supply solutions for pharma, biotechnology, and consumer health companies, and its mission is closely aligned with Novo Holdings’ purpose to invest for the benefit of people and the planet.” “We look forward to supporting the Catalent team as they build on their positive momentum and position the company for future growth to the benefit of customers and patients globally,” added Jonathan Levy, Senior Partner, Novo Holdings. With the completion of the transaction, holders of Catalent common stock are entitled to receive $63.50 per share in cash, representing a premium of approximately 47.5% to the 60-day volume-weighted average price as of February 2, 2024. Catalent is dedicated to delivering unparalleled service to pharma, biotech, and consumer health customers, supporting product development, launch, and full life-cycle supply. Powered by thousands of scientists and technicians and the latest technology platforms at more than 40 global sites, Catalent supplies billions of doses of life-enhancing and life-saving treatments for patients annually. The Foundation’s mission is to progress research and innovation in the prevention and treatment of cardiometabolic and infectious diseases as well as to advance knowledge and solutions to support a green transformation of society.